For many investors, Johnson & Johnson is a familiar name, but it’s worth understanding the company’s current state and future prospects, as it is no longer just a giant known for its consumer brands. Instead, it is a company that combines healthcare stability and technological development, building long-term value on multiple fronts.
J&J currently?
Healthcare is a defensive sector, but the company doesn’t rely solely on stability. The company operates in three areas – innovative medicine, MedTech, and the previously spun-off consumer business – with the first two being its growth drivers. In the pharmaceutical sector, products aimed at treating cancer and autoimmune diseases, in particular, continue strong development, even if biosimilars are starting to weigh on the sales of some brands. In the MedTech segment, the company benefits from technological advancements, such as the development of cardiac devices and surgical solutions.
Q4/2024 figures show the company’s investment in the future; revenue grew by approximately 5 percent, but profit decreased due to rising R&D costs. Over 5 billion dollars were directed straight to product development in the quarter alone – over 23 percent of revenue. This is not a sign of problems, but an indication that the company is building growth for the next decade now.
Strategic moves strengthen position
J&J’s planned acquisition in the neuroscience field (ITCI) and partnerships for developing new treatments expand its footprint, especially in the treatment of depression and psychiatric disorders. At the same time, the company aims for 5–7 percent annual growth until 2030.
About risks and their management
Patent expirations and biosimilar competition are quite possible, as are regulatory changes and potential lawsuits. Nevertheless, the company’s diversified structure, strong balance sheet, and long history of operating with regulations provide investors with a solid foundation.
In summary
Johnson & Johnson may not be the most media-sexy company, but it offers a combination of stability, dividends, and long-term growth potential. For an investor who values defensiveness but wants to be part of the technological disruption in healthcare, Johnson & Johnson can be a different kind of choice (or not 
).
Reading material and other such nonsense:
My main source of information was @TradingLady’s excellent pitching text, and I asked for permission to use it as a significant aid. If there are errors in my text, it is due to me; my possible misunderstandings, etc.
Thank you, TradingLady! 
); it doesn’t sound massive on the company’s scale, though 
